文献速递临床试验与 GCP流行病学与生物统计

多剂量随机试验中剂量监测与优化的三结局双准则最优设计

TODO: A Triple-Outcome Double-Criterion Optimal Design for Dose Monitoring-and-Optimization in Multi-Dose Randomized Trials.
PubMed 文献 · Stat Med · 2025-01-01

针对多剂量随机试验缺乏正式统计设计、实践中剂量选择常依赖描述性统计的问题,提出一种贝叶斯最优两阶段设计,采用灵活贝叶斯动态线性模型刻画剂量-反应关系,用双准则评估剂量可接受性与合意性,并引入三结局试验决策程序考虑临床外因素。通过系统校准算法确定样本量和贝叶斯后验概率界值以优化设计操作特性,并演示基于效用的风险-获益权衡同时评估毒性与疗效。广泛模拟研究显示该设计具有稳健的操作特性。

要点

  • 提出贝叶斯最优两阶段设计用于多剂量随机试验的剂量监测与优化。
  • 采用双准则评估剂量可接受性与合意性,并引入三结局决策程序。
  • 通过模拟研究验证设计在不同场景下具有稳健的操作特性。

核心结论

  • 所提出的贝叶斯最优两阶段设计可用于多剂量随机试验中的剂量监测与优化,模拟研究显示其具有稳健的操作特性。

研究设计与样本

  • 提出一种贝叶斯最优两阶段设计,采用灵活贝叶斯动态线性模型刻画剂量-反应关系,并通过系统校准算法确定样本量和贝叶斯后验概率界值。

主要发现

  • 采用双准则评估剂量可接受性与合意性,并引入三结局试验决策程序以考虑临床因素之外的剂量选择。
  • 演示了如何在本框架内基于效用的风险-获益权衡同时评估毒性与疗效。
  • 跨多种场景的广泛模拟研究显示该设计具有稳健的操作特性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Detecting the efficacy signal and determining the optimal dose are critical steps to increase the probability of success and expedite the drug development in cancer treatment. After identifying a safe dose range through phase I studies, conducting a multidose randomized trial becomes an effective approach to achieve this objective. However, there have been limited formal statistical designs for such multidose trials, and dose selection in practice is often ad hoc, relying on descriptive statistics. We propose a Bayesian optimal two-stage design to facilitate rigorous dose monitoring and optimization. Utilizing a flexible Bayesian dynamic linear model for the dose-response relationship, we employ dual criteria to assess dose admissibility and desirability. Additionally, we introduce a triple-outcome trial decision procedure to consider dose selection beyond clinical factors. Under the proposed model and decision rules, we develop a systematic calibration algorithm to determine the sample size and Bayesian posterior probability cutoffs to optimize specific design operating characteristics. Furthermore, we demonstrate how to concurrently assess toxicity and efficacy within the proposed framework using a utility-based risk-benefit trade-off. To validate the effectiveness of our design, we conduct extensive simulation studies across a variety of scenarios, demonstrating its robust operating characteristics.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Zhang J, Zhou H, Wages NA, et al. TODO: A Triple-Outcome Double-Criterion Optimal Design for Dose Monitoring-and-Optimization in Multi-Dose Randomized Trials. Stat Med. 2025. PMID: 40390185. doi:10.1002/sim.70090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。